Age and Genetics Drive Real-World CLL Treatment Choices

Why It Matters

The findings reveal how real‑world prescribing aligns with guideline gaps, guiding future recommendations and patient counseling on efficacy versus tolerability and logistics.

Key Takeaways

• Mutated IGHV strongly predicts use of fixed‑duration O‑Ven regimen
• TP53 or 17p deletions drive selection of zanubrutinib
• Patients >75 years mainly receive continuous BTK inhibitors for outpatient ease
• Second‑generation BTK inhibitors now dominate frontline use, displacing ibrutinib

Pulse Analysis

The past decade has transformed chronic lymphocytic leukemia therapy, moving from chemo‑immunotherapy to a suite of chemo‑free options. In France, five first‑line agents—ibrutinib, acalabrutinib, zanubrutinib, obinutumab‑venetoclax (O‑Ven) and venetoclax‑ibrutinib (Ven‑I)—are reimbursed, yet head‑to‑head trials in treatment‑naïve patients remain scarce. This vacuum pushes clinicians to rely on patient‑specific factors such as genetic risk, comorbidities, and practical considerations, creating a natural experiment captured by the new real‑world study.

The analysis of 282 patients across 25 centers identified two distinct prescribing clusters. Younger individuals (median 69 years) with mutated IGHV and low‑risk cytogenetics overwhelmingly chose the fixed‑duration O‑Ven regimen, valuing a defined treatment window. Conversely, older patients (median 78 years) bearing high‑risk TP53 or 17p deletions were steered toward continuous BTK inhibition, primarily zanubrutinib or acalabrutinib, reflecting concerns about cardiovascular toxicity and the appeal of oral outpatient therapy. Notably, second‑generation BTK inhibitors now account for nearly 90% of frontline BTK use, signaling rapid adoption of tolerability data from relapsed‑setting trials.

These patterns have immediate implications for guideline committees and payers. As real‑world practice favors genetics‑driven, age‑adjusted strategies, future recommendations may need to differentiate more clearly between fixed‑duration venetoclax combos and continuous BTK inhibitors, especially for high‑risk cohorts. Moreover, the convenience of oral BTK therapy must be weighed against emerging resistance mutations and long‑term adverse events. For patients and clinicians, the study underscores the importance of individualized counseling that balances efficacy, safety, and lifestyle factors, while health systems should anticipate shifting drug utilization and associated cost structures.